Scalper1 News
Spinal-product company NuVasive (NUVA) beat Wall Street’s expectations as it released preliminary Q4 results and 2014 guidance Wednesday morning, sending NuVasive stock up 9% to a three-year high on the stock market today. The company said Q4 revenue was about $189 million, up 14% from the year-earlier quarter and $12 million above analysts’ consensus. It didn’t give a bottom-line number but said full-year operating margin would “exceed guidance” Scalper1 News
Scalper1 News